chemieunternehmen.com

Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-an-integrated-drug-discovery-collaboration-with-asahi-kasei-pharma-japan-5432

Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP („Fibrocor“), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-mars-innovation-establish-strategic-partnership-to-launch-fibrocor-therapeutics-5430

Evotec AG today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/haplogens-novel-antiviral-target-partnered-with-evotec-published-in-nature-5428

Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH („Eternygen“) by becoming an investor in addition to being a pre-clinical drug discovery partner.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-eternygen-to-develop-novel-metabolic-disease-therapy-5426

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-enter-into-drug-discovery-collaboration-for-neurodegenerative-diseases-6

Evotec AG today announced the successful closing of the acquisition of 100% shares in Cyprotex PLC, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-acquisition-of-cyprotex-plc-5418

Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. („Forge“) to advance its novel Gram-negative antibiotic programme targeting „LpxC“ for the treatment of bacterial infections including those caused by drug resistant ’superbugs‘. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-forge-therapeutics-form-strategic-superbug-alliance-8

Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck’s portfolio of genome editing technologies with Evotec’s versatile screening platforms and disease expertise. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-merck-enter-into-agreements-to-collaborate-on-target-discovery-technologies-5414